Ying Buechler, Ph.D.

Chief Technology Officer

Ying Buechler, Ph.D., has served as our Chief Technology Officer since October 2022, has held prior roles as Senior Vice President of Development and Vice President of Development. As an experienced CMC leader, she has been responsible for strategy and execution of biopharmaceutical development and manufacturing, and responsible for building and leading the CMC team. Ying has over 25 years of biotech industrial experience in protein-based therapeutics development and manufacturing with several Biotech companies in San Diego. Before rejoining Ambrx in August 2018, she was Executive Director of Biologics Development and Manufacturing at aTyr Pharma, where she led the team comprising upstream and downstream process development, analytical and formulation development functions for 7+ years, successfully executed process development and manufacturing activities for multiple clinical programs. She was with Ambrx during the first 7-years of Ambrx, served as director of process development and characterization and project leader of Ambrx’s first program, leading the advancement of a new molecule to clinical development while maturing the novel Ambrx technology. Ying earned her Ph.D. and M.S. in Chemistry from University of California, San Diego, and B.S. in Chemistry from Peking University in Beijing, China.